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Ecotropic murine leukemia viruses (MLVs) recognize the third extracellular loop of the receptor, cationic amino acid transporter type 1
(CAT1). The CAT1 protein contains two conserved N-linked glycosylation sites in the third extracellular loops of the mouse, rat, and hamster
receptors (mCAT1, rCAT1, and hCAT1, respectively). Glycosylation of the rCAT1 and hCAT1 receptors inhibits ecotropic MLV infection of
CAT1-expressing cells, but that of the mCAT1 does not afford the cells this protection. As compared to the mCAT1 protein, the rCAT1 and
hCAT1 proteins possess three and six amino acid insertions, respectively, in the third extracellular loop. To determine whether these inserted
amino acids are associated with ecotropic MLV infection inhibition by glycosylation, several mutants of mCAT1 and rCAT1 receptors were
constructed. Of all the mutants generated in the present study, only rCAT1 mutant 1 exhibited detectable protein expression levels. The
rCAT1 mutant 1-expressing human NP2 cells were more susceptible to transduction by ecotropic MLV vectors than the wild-type rCAT1-
expressing cells. Tunicamycin, an N-glycosylation inhibitor, increased transduction titer in the wild-type rCAT1-expressing cells, but did not
do so in the cells expressing either the mCAT1 or rCAT1 mutation 1. An amino acid substitution in the glycosylation site of the wild-type
rCAT1 conferred higher infection susceptibility, but that of the rCAT1 mutant 1 did not. As with the wild-type mCAT1 and rCAT1 proteins,
the rCAT1 mutants were detected on the cell surface by immunofluorescence microscopy. Tunicamycin treatment did not affect cellular
distribution of the rCAT1 mutant 1, wild-type mCAT1 or rCAT1 proteins. These results indicate that the extra amino acids in the rCAT1 (as
compared to the mCAT1) are associated with inhibition of ecotropic MLV infection by the rCAT1 glycosylation.
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than mouse cells (Kubo et al., 2002; Takase-Yoden and
Watanabe, 1999). The ecotropic MLVs recognize the cell
surface receptor protein, CAT1, for viral entry (Albritton
et al., 1989). The CAT1 receptor is a multi-membrane
spanning protein and functions to transport cationic
amino acids across cell membranes (Kim et al., 1991;
Overbaugh et al., 2001; Sommerfelt, 1999; Tailor et al.,
2003; Wang et al., 1991). Previous studies have shown
that the envelope glycoprotein (Env) of ecotropic MLVs004) 82–91
Fig. 1. Effect of tunicamycin on ecotropic MLV vector transduction in
human TE671, mouse NIH 3T3, and rat F10 cells. The cells were treated
with tunicamycin (100 ng/ml) for 24 h, and inoculated with Fr-MLV vector.
This experiment was repeated many times. Representative result is
indicated.
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CAT1 (mCAT1) (Albritton et al., 1993; Yoshimoto et al.,
1993). There are two conserved N-linked glycosylation
sites proximal to the Env-binding motif in the loop of
CAT1 sequences that have been isolated from various
animals.
It has been reported that treatment of hamster CHO
cells with an N-linked glycosylation inhibitor, tunicamycin,
confers viral infection susceptibility to these cells (Eiden et
al., 1993, 1994; Miller and Miller, 1992). Tunicamycin
treatment of rat cells also enhances susceptibility to the
ecotropic MLV infection (Kubo et al., 2002; Tavoloni and
Rudenholz, 1997). This indicates that N-linked glycosyla-
tion of hamster and rat cells inhibits ecotropic MLV
infection. We recently reported that rat XC cells expressing
the receptor variant containing an amino acid substitution
at one of two glycosylation sites (xcCAT1) are more
susceptible to the ecotropic MLV infection than other rat
cells, showing that the xcCAT1 is more susceptible to the
ecotropic MLV infection than the wild-type rat CAT1
(rCAT1) (Kubo et al., 2002). These results indicate that the
sugar chains linked to hamster CAT1 (hCAT1) and rCAT1
are responsible for the complete and partial blocking of
ecotropic virus infection, respectively.
Infection of cells with human immunodeficiency virus
(HIV) (Chabot et al., 2000; Kuhmann et al., 2000;
Potempa et al., 1997; Talbot et al., 1995; Thordsen et
al., 2002), gibbon ape leukemia virus, amphotropic MLV
(Wilson and Eiden, 1991), and human endogenous virus
type W (Marin et al., 2003) are also suppressed by
receptor N-glycosylation. This suggests that viral receptors
themselves evolved a mechanism for glycosylation to gain
protection from viral entry. It is interesting to note that the
glycosylation status of HIV envelope proteins is altered
during disease progression for protection against HIV-
neutralization antibodies, suggesting that glycosylation of
the HIV Env protein inhibits the Env–antibody association
(Wei et al., 2003). This shows that the viruses and hosts
both use the glycosylation reactions for their co-evolution.
The mCAT1 protein is glycosylated, as are the rCAT1
and hCAT1 proteins. However, unlike rCAT1 and hCAT1,
mCAT1 glycosylation does not inhibit ecotropic MLV
infection (Kubo et al., 2002; Wang et al., 1996). When
amino acid sequences of the third extracellular loops of
mCAT1 (Albritton et al., 1989), rCAT1 (Takase-Yoden and
Watanabe, 1999; Wu et al., 1994), and hCAT1 (Eiden et
al., 1994) were compared, the rCAT1 and hCAT1 proteins
were found to have extra amino acids. To determine
whether these extra or inserted amino acid residues are
involved in ecotropic MLV infection inhibition by the
receptor glycosylation, we constructed several mutants of
the mCAT1 and rCAT1 receptors. The rCAT1 mutant 1,
which has one amino acid insertion and three amino acid
deletions resembling mCAT1, was more susceptible to the
ecotropic MLV vector transduction than the wild-type
rCAT1. N-glycosylation of the rCAT1 mutant 1 did notaffect transduction efficiency by ecotropic MLV vectors.
This result indicates that the mutations introduced into the
rCAT1 mutant 1 abrogate the inhibition of ecotropic MLV
infection by rCAT1 glycosylation.Results
rCAT1 is as susceptible to transduction as mCAT1 in TE671
cells
Ecotropic MLV vectors that express the Mo-MLV or
Friend MLV (Fr-MLV) Env protein were utilized to test
for cell transduction efficiency (Cosset et al., 1995). As
already reported (Kubo et al., 2002; Takase-Yoden and
Watanabe, 1999), rat F10 cells were less susceptible to
the Fr-MLV vector transduction than mouse NIH 3T3
cells, and treatment of rat F10 cells with tunicamycin
(100 ng/ml) increased the susceptibility more than 100-
fold (Fig. 1). To confirm that N-linked glycosylation of
the rCAT1 inhibits the ecotropic MLV vector trans-
duction, retrovirus vectors encoding C-terminally HA-
tagged mCAT1 and rCAT1 were inoculated into human
NP2, human HeLa, human TE671, rat F10, hamster
THK, or mink cell lines. Human 293T cells were co-
transfected with the HA-tagged CAT1-encoding MLV
vector, Mo-MLV Gag-Pol expression, and VSV-G expres-
sion plasmids. Cultured supernatant of the transfected
293T cells was inoculated into the target cells. The
retrovirus vector has a puromycin-resistant gene. Puro-
mycin-resistant cell pools were analyzed in the following
experiments. The ratio of transduction titer of the Fr-
MLV vector in rCAT1-expressing cells to that in
mCAT1-expressing cells was measured in each cell line.
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were 0.4–0.6 (Fig. 2A; P b 0.05), indicating that the
rCAT1 is less susceptible to vector transduction than the
mCAT1. The rCAT1-expressing TE671 cells, however,
were as susceptible as the mCAT1-expressing TE671
cells to the Fr-MLV vector transduction. Tunicamycin
treatment (100 ng/ml) increased transduction titer in the
rCAT1-expressing NP2 and HeLa cells (Fig. 2B; P b
0.05), but did not do so in the CAT1-expressing TE671
cells. Transduction efficiency of the Fr-MLV vector in
rCAT1-expressing mink cells was not affected by
tunicamycin treatment, because tunicamycin suppressed
mink cell growth more severely than did the HeLa,
TE671, or NP2 cells. The effect of tunicamycin on
vector transduction efficiency in CAT1-expressing rat F10
and hamster THK cells was not analyzed because the
tunicamycin treatment in these cell lines reportedly
confers higher transduction susceptibility of the original
rat and hamster cells (Eiden et al., 1994; Kubo et al.,
2002; Tavoloni and Rudenholz, 1997).Fig. 2. Transduction efficiency of mCAT1 and rCAT1 in various cell lines.
(A) Ratios of transduction titer by Fr-MLV vector in rCAT1-expressing
cells to that in mCAT1-expressing cells are indicated. (B) Effect of
tunicamycin on transduction efficiency by Fr-MLV vector in mCAT1- and
rCAT1-expressing cells was analyzed. Relative transduction titer in
tunicamycin-treated mCAT1- or rCAT1-expressing cells (gray bar) to that
in untreated cells (open bar) is indicated. This experiment was repeated
three times.Molecular weights of the rCAT1 and mCAT1 in these
cell lines were determined as an indication of glycosylation
status. We found that the molecular weights of the rCAT1
and mCAT1 proteins in the TE671 cells were lower than
they were in other tested cell lines (Fig. 3). This result
indicates smaller N-glucan links to the CAT1 protein in the
TE671 cells than in other cells. Therefore, the glycosylation
of rCAT1 is hypothesized to be less efficient at transducing
the Fr-MLV vector in TE671 cells.
Constitution of receptor mutants
Compared to the mCAT1 sequence illustrated in the
protein alignments (Fig. 4A), the rCAT1 and hCAT1
proteins possess three and six amino acid insertions,
respectively. To test whether these insertions are responsible
for ecotropic MLV infection inhibition by receptor glyco-
sylation, artificial mutations were introduced into the
mCAT1 and rCAT1 receptors, as shown in Fig. 4A. Briefly,
the mCAT1 mutant 1 was constructed to resemble wild-type
rCAT1, and as such has one amino acid deletion (position
223) and three amino acid insertions (positions 230–232).
The mCAT1 mutant 2 was constructed to resemble wild-
type hCAT1, and has six amino acid insertions (positions
224–226 and 230–232). The rCAT1 mutant 1 was cons-
tructed to resemble wild-type mCAT1, with one amino acid
insertion (position 223) and three amino acid deletions
(positions 230–232). The rCAT1 mutant 2 was constructed
to resemble hCAT1, and possesses four amino acid
insertions (positions 223–226).
As mentioned above, glycosylation of rCAT1 in TE671
cells does not inhibit transduction efficiency of the
ecotropic MLV vector, and tunicamycin treatment severely
suppresses mink cell growth (Fig. 2). Transduction titers
in the mCAT1-expressing HeLa cells were about 100
times lower than those in the mCAT1-expressing NP2
cells. Therefore, NP2 cells were used in following
experiments. We tested whether the transfections of the
HA-tagged CAT1 proteins were successful in the experi-
mental cell pools by examining protein expression. Our
findings confirmed that the mCAT1 mutants (1 and 2) and
rCAT1 mutant 2 proteins were not detectable. Protein
expression levels of the rCAT1 mutant 1 were detected at
a level similar to that of the wild-type mCAT1 and rCAT1
(Fig. 4B).
rCAT1 mutant 1 is more susceptible to ecotropic MLV
vector transduction than wild-type rCAT1
Cells expressing the rCAT1 mutant 1 were inoculated
with MLV vectors to determine susceptibility to ecotropic
infection. As illustrated in Fig. 5A, the mCAT-expressing
cell pool was more susceptible to the Mo-MLV vector
transduction than the rCAT1-expressing cell pool (P b
0.05). This finding corroborates those previously reported
(Kubo et al., 2002; Takase-Yoden and Watanabe, 1999).
Fig. 3. Expression of C-terminally HA-tagged mCAT1 and rCAT1 in various cell lines. Cell lysates were prepared from puromycin-resistant cell pools
expressing HA-tagged mCAT1 and rCAT1. The cell lysates were subjected to 7.5% polyacrylamide gel electrophoresis. Western immunoblotting was
performed using the anti-HA antibody. Molecular weight standard is indicated in left side.
Y. Kubo et al. / Virology 330 (2004) 82–91 85Interestingly, the rCAT1 mutant 1-expressing cell pool was
more susceptible to the Mo-MLV vector transduction than
the wild-type rCAT1-expressing cell pool (P b 0.05). This
result indicates that the mutations introduced into the rCAT1Fig. 4. Construction and expression of CAT1 mutants. (A) Amino acid sequence
mutants. A solid black dot indicates an amino acid deletion. A solid black bar indic
Expression of the CAT1 mutants were analyzed by Western immunoblotting usin
tagged mCAT1-, rCAT1-, and rCAT1 mutant 1-expressing NP2 cells. The cell lymutant 1 confer higher Mo-MLV vector transduction
susceptibility to the rCAT1 protein.
We also determined that, in a manner similar to that
determined for the Mo-MLV vector transduction by rCAT1alignments of the third extracellular loops of mCAT1, rCAT1, hCAT1, and
ates an identical amino acid. N-linked glycosylation sites are underlined. (B)
g the anti-HA antibody. Cell lysates were prepared from normal NP2, HA-
sates were electrophoresed on 7.5% polyacrylamide gels.
Fig. 5. Effect of tunicamycin on transduction efficiency by M-MLV and by
Fr-MLV and on molecular weight of the HA-tagged CAT1 protein. The
mCAT1-, rCAT1-, rCAT1 mutant 1-expressing NP2 cell pools were treated
with tunicamycin (100 ng/ml) for 24 h. (A, B) Transduction titers in
tunicamycin-treated (gray bar) or untreated (open bar) were measured.
Relative transduction titers to that in the untreated mCAT1-expressing NP2
cells are indicated. This experiment was repeated three times. (C) Cell
lysates were prepared from treated and untreated CAT1-expressing NP2
cells. Cell lysates were electrophoresed on 10% polyacrylamide gels.
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susceptible to the Fr-MLV vector transduction than the
rCAT1-expressing cells (Fig. 5B; P b 0.05). The transduction
titer of the Mo-MLV vector in the rCAT1-expressing cells
was about 40% of that in the mCAT1-expressing cells, while
the titer of the Fr-MLV vector in the rCAT1-expressing cells
was about 60% of that in mCAT1-expressing cells. The
transduction titer of theMo-MLV vector in the rCAT1mutant
1-expressing cells was about 65% of that in the mCAT1-
expressing cells, but titer of the Fr-MLV in the rCAT1 mutant
1-expressing cells was about 90% of that in the mCAT1-
expressing cells. This result indicates that the Fr-MLV vector
more efficiently transduces the rCAT1- and rCAT1 mutant 1-
expressing cells than the Mo-MLV vector.
Effect of tunicamycin on susceptibility of the rCAT1
mutant 1
In the next set of experiments, we analyzed the effect of
tunicamycin, an N-linked glycosylation inhibitor, on theMLV vector transduction susceptibilities of the mCAT1,
rCAT1, and rCAT1 mutant 1 proteins. The transduction
titers of the Mo-MLV and Fr-MLV vectors in the wild-type
rCAT1-expressing cell pool were increased by the tunica-
mycin treatment (Fig. 5A; P b 0.05). However, this effect
was not documented in the rCAT1 mutant 1-expressing cells
(Fig. 5B). Transduction titers of these ecotropic MLV
vectors in the untreated rCAT1 mutant 1-expressing cells
were comparable to those in the tunicamycin-treated rCAT1-
expressing cells. The tunicamycin treatment decreased the
molecular weights of the CAT1 proteins, and equal levels of
these CAT1 proteins were detected (Fig. 5C). These results
indicate that the mutations introduced into the rCAT1
mutant 1 abrogate of ecotropic MLV infection inhibition
by rCAT1 glycosylation.
Transduction titers of the Mo-MLV vector in the
tunicamycin-treated rCAT1- and rCAT1 mutant 1-expres-
sing cells were lower than those examined in the tunica-
mycin-treated mCAT1-expressing cells (Fig. 5A). However,
titers of the Fr-MLV vector in the tunicamycin-treated
rCAT1- and rCAT1 mutant 1-expressing cells were com-
parable to those in the tunicamycin-treated mCAT1-expres-
sing cells (Fig. 5B). This result indicates that the Fr-MLV
vector more efficiently infects the rCAT1-expressing cells in
a receptor glycosylation-independent manner.
Transduction susceptibility of glycosylation-defective CAT1
mutants
Susceptibility of rCAT1 to the ecotropic MLV vector
transduction was lower than that of mCAT1 in mink cells
(Fig. 2A). Tunicamycin treatment, however, did not
increase transduction efficiency of the ecotropic MLV
vector (Fig. 2B), because it severely inhibited growth of
mink cells. To exclude side effects of tunicamycin treat-
ment, susceptibility of NP2 cells expressing CAT1 mutants
that have amino acid substitutions at the glycosylation sites
was analyzed. An mCAT1 mutant, M3, has amino acid
substitutions at both of the glycosylation sites (Fig. 4A).
The xcCAT1 isolated from rat XC cells has an amino acid
substitution of Asn to Asp at position 236, as compared to
the rCAT1 sequence (Kubo et al., 2002). Accordingly, the
same amino acid substitution (Asn to Asp at position 236)
was artificially introduced into the rCAT1 mutant 1, and
the new construction was designated as rCAT1 mutant 1G
(Fig. 4A). NP2 cells expressing C-terminally HA-tagged
mCAT1 M3, rCAT1 mutant 1G, and xcCAT1 were
additionally constructed as above, and glycosylation was
assessed by molecular weight determination. The molec-
ular weights of the xcCAT1 and rCAT1 mutant 1G
proteins were lower than those of the rCAT1, mCAT1,
and rCAT1 mutant 1 proteins, as compared to their wild-
type CAT1 controls, presumably due to the mutation at one
of two glycosylation sites (Fig. 6B). The molecular weight
of the mCAT1 M3 protein was determined to be lower
than those of the xcCAT1 and rCAT1 mutant 1G proteins,
Fig. 6. Effect of amino acid substitutions at the N-linked glycosylation site
of the CAT1 on transduction efficiency by the Fr-MLV vector and on
molecular weight of CAT1 protein. (A) Glycosylation sites of mCAT1,
rCAT1, and rCAT1 mutant 1 were substituted. The mCAT1 M3 was
provided from Dr. Kabat (Wang et al., 1996). The xcCAT1 was isolated
from rat XC cells, and has an amino acid substitution at one of two
glycosylation sites (Kubo et al., 2002). This experiment was repeated three
times. (B) Cell lysates were prepared from normal, mCAT1-, mCAT1 M3-,
rCAT1-, rCAT1 mutant 1-, rCAT1 mutant 1G-, and xcCAT1-expressing
NP2 cells. The cell lysates were electrophoresed on 7.5% polyacrylamide
gels.
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due to the mutations at both of two glycosylation sites.
NP2 cells expressing the aforementioned mutants and
their corresponding wild-type CAT1 proteins were inocu-
lated with Fr-MLV vector containing LacZ reporter gene.
We observed that the rCAT1-expressing NP2 cells were less
susceptible to Fr-MLV vector transduction than the mCAT1-
expressing cells (Fig. 6A) as above (Figs. 2 and 5). The
xcCAT1-expressing cells were more susceptible than the
wild-type rCAT1-expressing cells (P b 0.05) as previously
reported (Kubo et al., 2002). The rCAT1 mutant 1-
expressing cells were more susceptible to MLV transduction
than the rCAT1-expressing cells as above (Fig. 5A), and
were as susceptible as those expressing the xcCAT1 protein
(Fig. 6A). The rCAT1 mutant 1G-expressing cells were as
susceptible as the rCAT1 mutant 1-expressing cells,
indicating that glycosylation of the rCAT1 mutant 1 does
not affect the ecotropic MLV vector transduction. Theseresults confirm that the naturally occurring amino acid
insertions found in the rCAT1 receptor (as compared to the
mCAT1 sequence) are responsible for the inhibition of
ecotropic MLV infection by the rat receptor glycosylation.
Cell surface expression of the rCAT1 mutants
To determine whether the mutations in the rCAT1
mutants 1 and 1G affect cellular distribution of the protein,
immunofluorescence microscopy was performed. The wild-
type mCAT1 and rCAT1 proteins, as well as the rCAT1
mutant 1 and mutant 1G proteins were detected on the
surfaces of almost all of the observed cells (Fig. 7). This
result indicates that the mutations had no effect on cellular
distribution of the rCAT1 protein. Also, cellular distribution
of the rCAT1 mutant 1, wild-type mCAT1, and rCAT1
proteins was not affected by the tunicamycin treatment (100
ng/Al; Fig. 7).Discussion
N-linked receptor glycosylation partially and completely
inhibited ensuing ecotropic MLV infection of rCAT1- and
hCAT1-expressing cells, respectively (Eiden et al., 1994;
Kubo et al., 2002; Miller and Miller, 1992; Tavoloni and
Rudenholz, 1997). Glycosylation of mCAT1, however, does
not inhibit infection by the MLV vectors (Kubo et al., 2002;
Wang et al., 1996). Compared to the mCAT1 protein, rCAT1
and hCAT1 have three and six amino acid insertions,
respectively, in their third extracellular loops, which are
recognized by the ecotropic Env protein (Fig. 4A). The
rCAT1 mutant 1 was engineered to possess one amino acid
insertion (Glu at position 223) and three amino acid
deletions (Ser, Leu, and Pro at positions 230–232) without
any substitutions. We observed similar MLV infection levels
between rCAT1 mutant 1- and wild-type mCAT1-expressing
cells, indicating that mutating this glycosylation site
removed the intermediary infection protection afforded by
the wild-type rCAT1 sequence (Figs. 5 and 6). The Glu at
position 223 (Fig. 4A) is not responsible for the loss of
glycosylation-sensitive infection, because the hCAT1 also
possesses this residue. Furthermore, although there are
several amino acid differences between the rCAT1 and the
mCAT1 proteins, these differences are not likely associated
with the glycosylation-sensitive MLV infection nature,
because, relative to wild-type rCAT1, the rCAT1 mutant 1
does not have any amino acid substitutions. However, these
amino acid differences should be involved in conferring the
higher susceptibility of the mCAT1 to the Mo-MLV vector
transduction than the rCAT1mutant 1 shown in Fig. 5A.
It has been reported that Mus dunni cells are susceptible
to Fr-MLV infection, but not to Mo-MLV by receptor
glycosylation (Eiden et al., 1993, 1994). Interestingly, M.
dunni CAT1 possesses six amino acid deletions similar to
those in mCAT1, as compared to the hCAT1 (Eiden et al.,
Fig. 7. Cell surface expression of the mCAT1, rCAT1, rCAT1 mutant 1, and rCAT1 mutant 1G proteins. The CAT1-expressing cells were cultured in chamber
slides, fixed with cold methanol, treated with mouse anti-HA antibody, followed by treatment with Cy3-conjugated anti-mouse IgG antibody. The cells were
observed under confocal fluorescence microscopy.
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containing an amino acid substitution from Ile to Val at
position 214 is susceptible to Mo-MLV infection, indicating
that this Ile is responsible for the resistance ofM. dunni cells
to the Mo-MLV infection by the glycosylation (Eiden et al.,
1993). The rCAT1 does not possess this Ile residue at the
corresponding position. The mechanism by which glyco-
sylation of the rCAT1 protein inhibits ecotropic MLV
infection may differ from the infection protection mecha-
nism of M. dunni receptor glycosylation.
Protein expression of the rCAT1 mutant 1 was detected in
the transfected cells, but those of the mCAT1 mutants 1 and 2
and rCAT1 mutant 2 were not. Furthermore, protein
expression of an HA-tagged form of the wild-type hCAT1
isolated from THK cells was not detected. Almost all of the
mutants we constructed for the experiments presented in the
current study, however, were not detectably expressed to
proteins in transfected cells. CAT1 is a multimembrane
spanning protein, and its expression is likely controlled by
unknown complex mechanisms (Dr. J.M. Cunningham and
Dr. L.M. Albritton, personal communication). Comprehend-
ing the nature of wild-type CAT1 protein folding is apt to
render clues as to how mutagenesis may disrupt the 3D
structure.
Cells overexpressing rCAT1 are more susceptible to
transduction than rat F10 cells
The mouse NIH 3T3 cells exhibited MLV vector
transduction sensitivity greater than 100-fold above therat F10 cells. The mCAT1-expressing NP2 cells con-
structed in this study were 2–3 times more susceptible to
transduction than the rCAT1-expressing NP2 cells. This
discrepancy may have occurred because the rCAT1-
expressing NP2 cells were constructed by stable trans-
duction with the rCAT1-containing retroviral vector. Thus,
rCAT1 expression was mediated by the Mo-MLV long
terminal repeat. The expression level of the rCAT1 protein
in the rCAT1-expressing NP2 cells would predictably be
much higher than that in rat F10 cells. Therefore, the
rCAT1-expressing NP2 cells were more susceptible to the
subsequent MLV transduction than were the rat F10 cells.
Although the expression level of the mCAT1 in the
mCAT1-expressing NP2 cells is expected to be much
higher than that in mouse NIH 3T3 cells, the transduction
titer of the ecotropic MLV vector in NIH 3T3 cells was in
actuality similar to that observed in the mCAT1-expressing
NP2 cells. This finding indicates that the mCAT1
expression level in NIH 3T3 cells saturates the receptor
activity. As a result, the ratio of transduction titer in the
rCAT1-expressing NP2 cells to that in the mCAT1-
expressing cells was much higher than the titration ratio
of rat F10 to mouse NIH 3T3 cells.
Mechanism of receptor glycosylation-mediated inhibition of
ecotropic MLV infection
The results reported here indicate that the mutations
introduced into the rCAT1 mutant 1 result in the loss of
glycosylation sensitive infection by the ecotropic MLV. The
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longer than that of the mCAT1 and rCAT1 mutant 1
proteins. Compared to rCAT1, hCAT1 has an additional four
amino acid insertion. It is likely that the amino acid
insertions in the hCAT1 protein confer the receptor
glycosylation-mediated MLV infection vulnerability ob-
served in the present study. Unfortunately, protein expres-
sion of the mCAT1 mutant 2 and rCAT mutant 2 has yet to
be detected.
We hypothesize a mechanism by which glycosylation of
the rCAT1 and hCAT inhibits ecotropic virus infection as
follows (Fig. 8). In the third extracellular loop of the
mCAT1 (Fig. 8, bottom panel), the ecotropic Env binding
motif and the glycosylation sites exist separately in the right
and left sides of the extracellular loop, respectively. The
third extracellular loop of hCAT1 is longer than that of
mCAT1 by the number of amino acid insertions. The
hCAT1 insertions occur N-terminal to the glycosylation site,
and the top of the hCAT1 third extracellular loop is rotated
to N-terminal side. This rotation causes a repositioning of
the glycosylation site to the right side of the loop. As the
result, the sugar chain of hCAT1 masks the Env bindingFig. 8. Proposed mechanism by hCAT1 and rCAT1 glycosylation prevents
ecotropic virus infection. The third extracellular loops of the hCAT1 (top),
rCAT1 (middle), and mCAT1 (bottom) are shown. Each open circle
indicates one amino acid residue. Black closed circles in the hCAT1 panel
indicate amino acid residues that are deleted in rCAT1 and mCAT1 panels.
Black closed circles in the rCAT1 indicate amino acid residues that are
deleted in the mCAT1 panel. Gray closed circles indicate ecotropic Env
binding domain. Thick black lines denote the N-linked glucan.motif, and suppresses the ecotropic MLV infection. The
third extracellular loop of rCAT1 is shorter than that of
hCAT1, but longer than that of mCAT1. Thus, rCAT1 is
intermediate in size and infection sensitivity to mCAT1 and
hCAT1. The intermediary status of rCAT1 suggests a
functional correlation between protein size and infection
vulnerability, although precise understanding of the glyco-
sylation-mediated inhibition of ecotropic MLV infection
remains elusive, pending high-dimensional 3D structure
determination of the CAT1 protein.
Co-evolution of the virus and receptor
Based on the present results, we propose co-evolution of
the ecotropic retrovirus and its receptor as follows. We
know that N-linked glycosylation of the mCAT1 does not
inhibit ecotropic virus infection. The mCAT1 protein
evolved to resemble the rat type CAT1 through the addition
of a few amino acids to provide protection against ecotropic
virus infection. Ecotropic MLV evolved to overcome this
glycosylation mask, in a manner similar to that evolved by
Fr-MLV and its neuropathogenic variants. It has been
reported that these MLVs efficiently infect rat and hamster
cells as compared to other ecotropic MLVs (Eiden et al.,
1994; Ishimoto, 1985; Masuda et al., 1996; Takase-Yoden
and Watanabe, 1999). Furthermore, the CAT1 evolved to
the hamster type receptor by additional amino acid
insertions, and gained complete resistance to ecotropic
MLVs. The studies conducted herein underscore the
importance of N-glycosylation to bestow ecotropic viral
infection sensitivity to CAT1-expressing cells, and provide
additional evidence of CAT1/MLV co-evolution, suggesting
future avenues of experimentation.Materials and methods
Expression plasmids
A cDNA clone of mCAT1 was kindly provided by Dr.
J. M. Cunningham (Harvard Medical School, USA)
(Albritton et al., 1989). A plasmid encoding the mCAT1
M3 was kindly provided by Dr. D. Kabat (Oregon Health
Science University, USA). DNA clones of rCAT1 and
xcCAT1 were isolated from rat XC cells by our research
group (Kubo et al., 2002), and the amino acid sequence
was identical to that already reported (Takase-Yoden and
Watanabe, 1999; Wu et al., 1994). PCR was performed
on these cDNA clones as template using following
primers for C-terminal HA tagging: 5V-TTACTGCAGA-
CAGATTTGCTCAGCGCGATG-3V and 5V-TCATGCG-
TAATCCGGAACATCGTACGGGTATTTGCACTGGTC-
CAAGTTGCT-3V. The latter antisense primer possesses
the HA epitope sequence as already reported (Kubo et
al., 2003). The PCR product was cloned into pTargeT
vector (Promega) by TA cloning. The EcoRI–NotI
Y. Kubo et al. / Virology 330 (2004) 82–9190fragment containing the HA-tagged CAT1 sequence was
subcloned into pMXpuro retroviral vector DNA (Onishi
et al., 1996). A VSV-G expression plasmid (pHEF-
VSVG) was obtained from Dr. L. Chang through the
AIDS Research and Reference Reagent Program, Division
of AIDS, NIAID, NIH, USA (Chang et al., 1999).
Mutagenesis
PCR mutagenesis was performed on the HA-tagged
mCAT1 and rCAT1 expressing plasmids using 5V-phospho-
rylated BamX (5V-CTATAGGGCGAATTCCGATCCTTGC-
TAGCC-3V) and mutation primers. Nucleotide sequences of
the mutation primers used to construct the mCAT1 mutants
1, and 2, and those for rCAT1 mutants 1, 2 and 1G were as
follows: 5V-GTATTTCACGTTTGTGTCGTTGTTGTTA-
CAAAGAGGGCTGGAGAAATTCTCCGTGACTG-3V, 5V-
GTATTTCACGTTTGTGTCGTTGTTGTTACAAA-
GAGGGCTGGAGAAATTCAAGAAGTCCTTCTCCGTG
AGCTG-3V, 5V-GTATTTCACGTTTGTGTCATTGTTCC-
CACAGGATTTATTCTCCTCCGTGAGCTG-3V, 5V-
GTATTTCACGTTTGTGTCATTGTTCCCACAGA-
GAGGA CTGGATTTATTCAAGAAGTCCTCCTCCGTG
AGCTG-3V, and 5V-GTATTTCACGTTT GTGTCATCG-
TA`TCCCACAGGATTTATTCTCCTCCGTGAGCTG-3V,
respectively. The BamX primer has a nucleotide sub-
stitution to destroy a unique BamHI site of pTargeT
vector. These primers were synthesized by Nissinbo Inc.
(Japan). These primers amplified an approximately 0.9-kb
fragment, which in turn provided PCR primers to am-
plify the complete plasmid containing the desired
mutations. The PCR product was treated with BamHI
(TAKARA) to digest the template plasmid, and was
transformed into E. coli DH5a competent cells
(TAKARA). The EcoRI–NotI fragment containing the
HA-tagged CAT1 mutant sequence was subcloned into
the pMXpuro retroviral vector DNA. The nucleotide
sequence of the mutant was confirmed by sequencing
(TAKARA or Genenet).
Cells
Human glioma NP2 (Soda et al., 1999), TELCeB6
(Cosset et al., 1995), 293T, mink, rat F10, mouse NIH
3T3, and hamster THK cells were cultured in Dulbecco’s
modified Eagle’s medium (Sigma, USA) at 37 8C in 5%
CO2. The culture media were supplemented with 8% fetal
bovine serum (Biofluids). HA-tagged CAT1-expressing
NP2 cells were constructed as follows. 293T cells were
transfected with the Mo-MLV gag-pol (3 Ag), HA-tagged
CAT1-encoding retrovirus vector (3 Ag), and VSV-G
expression plasmids (3 Ag) by the TransIT LT1 regent
(30 Al) (Mirus). The cells were washed 24 h after
transfection, and cultured for 24 h in fresh medium.
Culture supernatant of the transfected cells was inoculated
into NP2 cells. The inoculated cells were selected bypuromycin (5 Ag/ml). The puromycin-resistant cell pool
was utilized in this study.
Transduction assay
The ecotropic retrovirus vector encoding the LacZ
gene was generated by stable transfection of TELCeB6
cells, which express the Mo-MLV gag-pol genes and
LacZ-containing retroviral vector genome (Cosset et al.,
1995), with the wild-type Mo-MLV (Kubo and Ama-
numa, 2003) or Fr-MLV (Obata et al., 1984) Env
expression plasmid. Target cells (2  105) were plated
into a 6-cm culture dish, and cultured for 24 h in
presence or absence of tunicamycin (100 ng/ml). The
cells were washed with medium to remove tunicamycin,
and inoculated with the retrovirus vector in presence of
polybrene (4 Ag/ml). After being cultured for an addi-
tional 24 h in fresh medium, the cells were stained with
5-bromo-4-chloro-3-indolyl-h-d-galactopyranoside (X-
Gal) (Wako), and blue cells were counted to estimate
transduction titer.
Western immunoblotting
The HA-tagged CAT1-expressing cells (2  105) were
plated and cultured for 48 h. The cells were cultured for
additional 24 h in presence or absence of tunicamycin (100
ng/ml). Cell lysates were subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (7.5% or 10%),
and subsequent Western immunoblotting using a mouse
anti-HA monoclonal antibody (Covance) and horseradish
peroxidase-conjugated anti-mouse IgG antibody (Bio-Rad).
Immunofluorescence microscopy
The HA-tagged CAT1-expressing NP2 cells were cul-
tured in poly-d-lysine-coated 8-well culture slide (Becton
Dickinson) in the presence or absence of tunicamycin (100
ng/ml) for 24 h. The cells were fixed with cold methanol,
blotted with the anti-HA antibody and then with an anti-
mouse IgG conjugated with indocarbocyanine (Cy3)
(Sigma). The cells were observed with a confocal fluo-
rescence microscope (Leica).Acknowledgments
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